Kojima Taiki, Yoshikawa Kazuhiro, Saga Shinsuke, Yamada Tomohiro, Kure Shigehiro, Matsui Takanori, Uemura Takanori, Fujimitsu Yasunobu, Sakakibara Masatoshi, Kodera Yasuhiro, Kojima Hiroshi
Department of Gastroenterological Surgery, Aichi Cancer Center Aichi Hospital, Aichi, Japan.
J Surg Res. 2009 Jul;155(1):13-7. doi: 10.1016/j.jss.2008.07.024. Epub 2008 Aug 27.
Recently, several authors reported on the Protein Chip approach to analyze serum. They used SELDI-TOF-MS (surface enhanced laser desorption/ionization-time of flight-mass spectrometry) to identify patients with cancers of various origins in a highly sensitive and specific manner. In the current study, a similar approach was employed to analyze the serum of patients with various stages of gastric cancer.
Control serum specimens from patients with gastritis (n = 19) and those with gastric cancer (Stage I: n = 6, Stage II or III: n = 6, Stage IV: n = 6, total: n = 18) were collected and analyzed by the Protein Chip biomarker system (Bio-Rad, Japan), a platform for SELDI-TOF-MS, and protein profiles were obtained and compared. The cation exchange chip (CM10) and the anion exchange chip (Q10) were used for processing before TOF-MS.
nine proteins were significantly over-expressed (P < 0.05, Student t-test) in patients with gastric cancer compared to patients with gastritis. Among them, four protein masses with 2929 m/z, 3293 m/z, 3371 m/z, and 4213 m/z were found to be differentially expressed solely in patients suffering from peritoneal dissemination. All peaks were processed on CM10 chips. Employing one data mining method, CART (classification and regression trees), gastric cancer patients with peritoneal dissemination were successfully separated from those who had no peritoneal seeding.
A validation study with a larger number of samples is mandatory; however, the detected peaks here might be candidates for biomarkers of peritoneal dissemination and/or gastric cancer. Moreover, further analysis of these four proteins might be helpful in revealing the mechanism of peritoneal dissemination, which at present has no cure.
最近,几位作者报道了用蛋白质芯片方法分析血清。他们使用表面增强激光解吸/电离飞行时间质谱(SELDI-TOF-MS)以高度敏感和特异的方式识别各种起源癌症的患者。在本研究中,采用了类似的方法来分析不同阶段胃癌患者的血清。
收集来自胃炎患者(n = 19)和胃癌患者(I期:n = 6,II期或III期:n = 6,IV期:n = 6,总计:n = 18)的对照血清标本,并用蛋白质芯片生物标志物系统(日本伯乐公司)进行分析,该系统是SELDI-TOF-MS的一个平台,获得蛋白质谱并进行比较。在进行TOF-MS之前,使用阳离子交换芯片(CM10)和阴离子交换芯片(Q10)进行处理。
与胃炎患者相比,胃癌患者中有9种蛋白质显著过度表达(P < 0.05,学生t检验)。其中,发现有4个质荷比分别为2929 m/z、3293 m/z、3371 m/z和4213 m/z的蛋白质仅在腹膜播散患者中差异表达。所有峰均在CM10芯片上处理。采用一种数据挖掘方法——分类与回归树(CART),成功地将有腹膜播散的胃癌患者与无腹膜种植的患者区分开来。
必须用更多样本进行验证研究;然而,这里检测到的峰可能是腹膜播散和/或胃癌生物标志物的候选物。此外,对这四种蛋白质的进一步分析可能有助于揭示目前无法治愈的腹膜播散机制。